Skip to main content
Premium Trial:

Request an Annual Quote

Bellbrook Names Cambio UK Distributor for Transcreener Products

NEW YORK (GenomeWeb News) – BellBrook Labs today announced a revised distribution agreement with Cambio to include BellBrook's full Transcreener product line of HTS assays.

Under the terms of the revised deal, Cambio becomes the exclusive distributor of BellBrook's Transcreener HTS assays in the UK. Cambio will also distribute BellBrook's new Transzyme product line of turnkey methyltransferase assay kits combining precalibrated purified methytransferase enzymes and substrates from Reaction Biology with BellBrook's Transcreener Epigen Methyltransferase detection reagents.

BellBrook said the deal is its first granting exclusive distribution rights to a territory in Europe. Further financial and other terms were not disclosed.

The Transcreener HTS assays cover thousands of enzymes, including kinases, as well as emerging target families, such as methyltransferases, GTPases, and glycosyltransferases, BellBrook said, adding that the Transcreener assays are the only technology for direct detection of nucleotide enzyme products.

In March 2012, Cambio was named UK distributor for BellBrook's Transcreener HTS assays and iuvo Microconduit Array Platform.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.